Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of “Buy” from Brokerages

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) have been given an average recommendation of “Buy” by the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and four have given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $78.9412.

Several research analysts have weighed in on the stock. National Bankshares set a $80.00 target price on shares of Revolution Medicines in a research report on Friday, October 17th. Mizuho assumed coverage on Revolution Medicines in a report on Tuesday, October 21st. They issued an “outperform” rating and a $90.00 price target on the stock. Wolfe Research started coverage on Revolution Medicines in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 price objective for the company. Raymond James Financial boosted their target price on Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a research report on Friday, October 17th. Finally, HC Wainwright lifted their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th.

Revolution Medicines Stock Down 0.4%

RVMD opened at $96.15 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05. Revolution Medicines has a 12 month low of $29.17 and a 12 month high of $124.49. The stock has a market capitalization of $18.59 billion, a P/E ratio of -18.60 and a beta of 1.01. The business has a 50 day simple moving average of $92.12 and a 200-day simple moving average of $63.35.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same quarter in the prior year, the business earned ($0.94) earnings per share. On average, equities analysts anticipate that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In related news, insider Stephen Michael Kelsey sold 5,447 shares of Revolution Medicines stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total transaction of $418,438.54. Following the completion of the sale, the insider owned 278,600 shares in the company, valued at approximately $21,402,052. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark A. Goldsmith sold 60,000 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $75.08, for a total transaction of $4,504,800.00. Following the completion of the transaction, the insider directly owned 247,863 shares of the company’s stock, valued at $18,609,554.04. The trade was a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 213,792 shares of company stock worth $17,948,440. 8.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors have recently modified their holdings of RVMD. Indiana Trust & Investment Management Co purchased a new stake in Revolution Medicines in the 4th quarter worth approximately $32,000. Torren Management LLC acquired a new position in Revolution Medicines in the fourth quarter valued at $33,000. CWM LLC increased its stake in Revolution Medicines by 171.3% in the second quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after purchasing an additional 579 shares during the last quarter. GAMMA Investing LLC lifted its position in Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after buying an additional 260 shares during the period. Finally, Darwin Wealth Management LLC acquired a new stake in Revolution Medicines in the 4th quarter worth about $40,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.